The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- Podcast 190 – Emergencies with a Side of Hypertension - January 9, 2017
- EMCrit 189 – End of Year Grab Bag - December 28, 2016
- Podcast 188 – Rudeness Part II (the Brindley Sessions) - December 12, 2016